Global Pharmaceutical R&D - Some Political Economy & Public Policy Considerations
Download as PPTX, PDF1 like684 views
The document discusses the challenges and considerations in balancing access and innovation in global pharmaceutical research and development (R&D), particularly in relation to new medicines and their affordability. It presents various policy solutions, including stronger patents, compulsory licenses, and differential pricing, while highlighting tensions between developed and developing countries. Additionally, the author reflects on the need for innovative approaches to address public health issues and the complex dynamics of pharmaceutical markets.
Global Pharmaceutical R&D - Some Political Economy & Public Policy Considerations
- 1. GLOBAL PHARMACEUTICAL R&D Some Political-Economy & Public Policy Considerations CHIRANTAN CHATTERJEE IIM-Bangalore Sept 1 2014 International Infectious Diseases & Global Health Training Program Karnataka Health Promotion Trust Sources for data & figures: World Wide Web (unless otherwise mentioned)
- 2. Do you believe that New Medicines are Good for Society? Source: Lichtenberg 2005
- 3. New Medicines Seem to be Good for Society Source: Lichtenberg 2005
- 4. But New Medicines are costly raising Affordability Issues: Case of Antiretrovirals Source: http://apps.who.int/medicinedocs/documents/s18716en/s18716en.pdf
- 5. How can you balance Access versus Innovation in Pharmaceutical R&D? - Solutions? - No Easy Answers - Innovator Firms Focus on R&D spending in therapeutic markets (usually in rich-world diseases) that give them returns on R&D with their monopoly rents protected through patents. - But when poor needs those drugs like in HIV or Cancer, patents are often side-stepped, causing tussles between innovators & imitators, developed and developing countries. - But if patents are disrespected, no innovation might happen
- 6. A Classic Egg-Chicken-Egg Public Policy Problem
- 7. Boiling into Policy Disputes between Countries
- 8. What Might be a Solution? Some Policy Levers 1) Stronger Patents in Developing & Least Developed Countries? 2) Compulsory Licenses? 3) Differential Pricing? 4) Advanced Market Commitments as in case of Vaccines? 5) Priority Review Vouchers? 6) Health Impact Fund? 7) ALS Ice-Bucket Challenge? 8) Any thing else?
- 9. TRIPS & Global Public Health
- 11. Differential Pricing Source: Chatterjee, Kubo, Pingali 2014
- 12. Differential Pricing Source: Chatterjee, Kubo, Pingali 2014
- 14. Priority Review Voucher (Ridley et.al) Drugs for Neglected Diseases https://www.youtube.com/watch?v=LSlF4hT8TYg
- 15. Health Impact Fund Thomas Pogge – Yale University https://www.youtube.com/watch?v=7HLLq-FY57I
- 16. ALS Ice-Bucket Challenge A Developed World Fad or a Real Panacea to Finance Pharmaceutical R&D?
- 17. ALS Ice-Bucket Challenge A Developed World Fad or a Real Panacea to Finance Pharmaceutical R&D? Source: http://www.vox.com/2014/8/20/6040435/als-ice-bucket-challenge-and-why-we-give-to-charity-donate
- 18. Some Other Considerations Here Universal Health Coverage & Government Funded National Health Insurance Schemes? Price Control of Drugs? The role of Low-End Disruptors? State Procurement Agencies like TNSMC/Locost (Public or Private)? Quality of Medicines/Counterfeit/Banned Medicines? Role of Alternative Medicines (the search for Sanjeevani) Biologics & Bio-similars? Anything else?
- 19. So No Answers from me – Still Mulling! - But maybe one needs to think about: A Tiered Therapeutic Market Approach. Contemplate the role of Innovation Prizes (like PRV, HIF) A Straight-Up Patents/No-Patents World might not be a solution
- 20. Giants on Whom we Stand (and there are many) Joseph Stiglitz, Boldrin & Levin Jenny Lanjouw (ex-UC Berkeley), F. M. Scherer (Kennedy-Harvard), Iain Cockburn (Boston-U), Henry Grabowski & Frank Sloan (Duke-U), Richard Manning (Bates & White) Pinelopi Goldberg (Yale), Anita McGahan (Rotman-Toronto), Margaret Kyle (Toulouse U.), Yi Qian (UBC-Northwestern), Panle Jia (Cornell), Antara Dutta (Bates & White) Dana Goldman, Tom Philipson, Darius Lakdawalla, Neeraj Sood (USC/Precision Health Economics) Ashish Arora (Duke), Lee Branstetter (Carnegie-Mellon), Matt Higgins (Georgia Tech), Mariko Sakakibara (UCLA) Sudip Chaudhuri (IIM-Calcutta) and Shubham Chaudhuri (World Bank) And some others who are on this journey to unravel this puzzle like me.
- 21. Thank You for your time chirantan@alumni.cmu.edu or chirantan.chatterjee@iimb.ernet.in